Graeme Martin

Graeme Martin


Dr. Graeme Martin (PhD) is a pharmaceutical industry veteran with more than 40 years of multinational Pharma and Biotech R&D experience in Europe, ASA and Japan.

He was President and CEO of Takeda Ventures, Inc., the corporate venture arm of Takeda Pharmaceuticals, and during a tenure of 14 years, he oversaw strategic investments into a portfolio of 31 early stage companies representing >$100m under management. He served on the Board of 16 of these companies.

Before turning to corporate venture, Dr. Martin held senior R&D positions at Roche (USA), GlaxoWellcome (UK) and Wellcome Research Laboratories (UK), where he led a number of therapeutic discovery initiatives resulting in three IND submissions and ultimately, the launch of ZomigĀ®, marketed worldwide for the acute treatment of migraine. He is the author of more than 85 peer reviewed scientific papers and book chapters.

Dr. Martin received his Bachelor of Science degree in Pharmacology from the University of Bath, and his doctorate from University College, London, UK.